ICGT ICG Enterprise Trust

Voting Rights and Capital

Voting Rights and Capital

ICG Enterprise Trust plc (the “Company”)

1 April 2025

        

Total Voting Rights

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows.

At the close of business on the 31 March 2025, the Company had 72,913,000 Ordinary shares in issue, of which 9,048,808 were held in Treasury. Therefore, the total number of voting rights in the Company is 63,864,192.



The above figure 63,864,192 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Analyst / Investor enquiries:

Chris Hunt

Shareholder Relations, ICG

+44 (0) 20 3545 2020

Andrew Lewis

Company Secretary, ICG

+44 (0) 20 3545 1344

Media:

Clare Glynn

Corporate Communications, ICG

+44 (0) 20 3545 1395



EN
01/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ICG Enterprise Trust

 PRESS RELEASE

ICG Enterprise Trust executes secondary sale

ICG Enterprise Trust executes secondary sale 2 April 2025 ICG Enterprise Trust executes secondary sale ICG Enterprise Trust (“ICGT”) is pleased to announce the sale of eight mature primary fund investments, generating net cash proceeds of £62 million. The sale was executed at a discount of 5.5% to the 30 September 2024 valuation, having received significant buyer interest. It realises a return of 1.6x invested cost (15% IRR) to ICGT, and releases undrawn commitments of £10m. The proceeds have been received and will be deployed into opportunities in line with ICGT’s investment objectiv...

Mark Thomas ... (+2)
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: April 2025

Feature article: 2024 pharma statistics An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024. The year was characterised by 9.2% underlying (ex-COVID-19) growth. Much of the growth was driven by recently launched ant...

 PRESS RELEASE

Voting Rights and Capital

Voting Rights and Capital ICG Enterprise Trust plc (the “Company”) 1 April 2025        Total Voting Rights In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows. At the close of business on the 31 March 2025, the Company had 72,913,000 Ordinary shares in issue, of which 9,048,808 were held in Treasury. Therefore, the total number of voting rights in the Company is 63,864,192.The above figure 63,864,192 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify th...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 1 April 2025 Transaction in Own Shares The Company announces that on 31 March 2025 it bought back 100,000 of its own shares, to be held as treasury shares, at an average price of 1259 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 9,163,808.Total shares in issue excluding treasury shares following settlement of this purchase: 63,749,192. The Company has bought back these shares under the authority granted by shareholders at its Annual ...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 31 March 2025 Transaction in Own Shares The Company announces that on 28 March 2025 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1267 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 9,063,808.Total shares in issue excluding treasury shares following settlement of this purchase: 63,849,192. The Company has bought back these shares under the authority granted by shareholders at its Annual ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch